Atossa Genetics, Inc.
ATOS, The Breast Health Company(TM), has entered into a
contractual agreement with FedMed, Inc., one of the largest
proprietary Preferred Provider Organization (PPO) networks in the
U.S., for diagnostic laboratory testing. FedMed's network is
comprised of more than 550,000 providers, including 4,000 hospitals
and more than 60,000 ancillary facilities, serving over 40 million
Americans.
Atossa's agreement with FedMed will give FedMed's participating
providers and its clients' members greater access to Atossa's tests,
including the ForeCYTE Breast Health Test and the ArgusCYTE Breast
Health Test.
The stock is up more than 22 percent at last check.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in